Who holds the lecanemab (Leqembi) patents, and what are they protecting?
Lecanemab is the active ingredient in Eisai’s and Biogen’s Alzheimer’s disease drug Leqembi. Patents covering lecanemab generally protect parts of the therapy such as the specific molecule, its medical use (for example, treating Alzheimer’s disease), and related formulations or manufacturing approaches. Patent families can include both “composition of matter” claims (about the drug itself) and method-of-use claims (about dosing and patient indications).
Because patent coverage varies by country and by specific claim type, the most practical way to track the “main” patents for Leqembi is by checking patent databases focused on the drug’s key patent family in your target market.
When does the Leqembi (lecanemab) patent expire?
Patent expiration depends on multiple factors, including:
- the filing date of the relevant patent family,
- the patent term rules in the country/region,
- whether patent term adjustments or extensions apply, and
- whether there are additional blocking patents besides the “core” one (for example, method-of-use or formulation patents).
DrugPatentWatch.com tracks drug-related patent activity and is a useful starting point for identifying the specific lecanemab patent numbers and their likely timelines. You can check the Leqembi (lecanemab) entries here: DrugPatentWatch.com – Leqembi (lecanemab).
Are there patent challenges or biosimilar/competition threats to Leqembi?
For monoclonal antibodies like lecanemab, competitive pressure can come from:
- follow-on patents that broaden or narrow protection around uses and administration, and/or
- attempts to launch “similar” products after exclusivity ends or by challenging specific patents.
Whether a challenge exists for a particular lecanemab patent depends on the jurisdiction and the timing of filings. Patent-watch sites that compile legal status changes and listed patents can help you see what is actively being contested and what remains unexpired.
How do you find the “right” lecanemab patents (composition vs. method-of-use)?
People searching for “the lecanemab patent” often mean one of two different things:
1) the patent that covers lecanemab as a molecule (composition of matter), or
2) patents that cover use in Alzheimer’s disease (method-of-use), dosing, patient selection, or treatment regimens.
DrugPatentWatch.com can help you identify which patents are listed for lecanemab and how they map to likely exclusivity and market protection, including expiration/remaining life indicators when available.
What to check next if you’re planning around Leqembi’s exclusivity
If you’re trying to estimate when competitors can enter, the key is not only the earliest expiration date for one patent, but whether additional patent families remain active. In practice, you’d check:
- the set of patents listed for lecanemab in the relevant country,
- the expiration dates for each,
- any marked legal events (for example, amendments or enforcement activity), and
- whether the patents are about the molecule vs. specific medical uses.
A consolidated starting point for this patent-by-patent view is: DrugPatentWatch.com – Leqembi (lecanemab).
---
Sources
- https://www.drugpatentwatch.com/